

# EARNINGS RELEASE 2Q | 2024

08.august.2024

Tudo  
pra você  
ficar bem.





# Contents



1.	Highlights .....	2
2.	Revenues .....	6
3.	Costs and Expenses .....	8
4.	EBIT and EBITDA .....	10
5.	Net Financial Result .....	11
6.	Net Income/(Loss) .....	12
7.	Debt And Leverage .....	13
8.	Cash Flow.....	14



Earnings Video Conference  
August, 09<sup>th</sup> 2024 (Friday)  
09am Brasília | 08am EST



Zoom Webcast in Portuguese  
(Simultaneous translation to English)

## HIGHLIGHTS

Belo Horizonte, August 08, 2024 - **Rede Mater Dei de Saúde** (“Mater Dei” or “Company”) (B3: MATD3) announces its results for the second quarter of 2024 (2Q24). The financial statements presented in this report refers to the consolidated figures in Reais (BRL) million, except when otherwise indicated. The comparisons are made with the second quarter of 2023 (YoY comparison) and the first quarter of 2024 (QoQ comparison). The quarter information follows the Brazilian and International (IFRS) accounting rules and were revised by independent auditors.

### Centro de Saúde Norte Divestment

On May 30, 2024, was announced the divestiture of its corporate interest equal to 70% of Centro Saúde Norte S.A.(“CSN”) capital stock, Hospital Porto Dias holding. With the implementation of the Operation, Mater Dei will end its activities along with Hospital Porto Dias complex. **The Operation strengthens the Company’s financial discipline, through a portfolio adjustment in a challenging moment for the sector, decreasing its exposition to risk and boosting its cash position with an considerable improvement in receivables, working capital and net indebtedness of the Company.** Completion of the Operation is subject to fulfillment of certain precedent conditions, which was already approved by the shareholders (EGM), bondholders (AMB) and by the Brazilian Antitrust Authority (CADE).

For the quarter, following the accounting rules, due to the event outlined above, the Company allocated on its balance sheet CSN’s asset as available to sale. This accounting results in a reduction of BRL 744 million of the Company’s investment. For results presentation, the value of this loss is being excluded for a better comparison between the periods.

### Operational and Financial Highlights

- ✚ **Occupancy rate:** growth of 2.8pp YoY and drop of 3.5pp QoQ, reaching 75.6% in the quarter. If patient Day Hospital are taken in account, this rate reaches 79.2%;
- ✚ **Patient-day:** increase of 5.8% YoY and stable against last quarter. In the semestral comparison, there was a growth of 9.4%;
- ✚ **Average Ticket:** reached BRL 2.20 million per used bed in the quarter, a growth of 1.5% compared to 2Q23 and of 0.6% against the first quarter of 2024. In the year to date reached BRL 2.20 million per used bed;
- ✚ **Net Revenue:** totaled BRL 585 million in the quarter, a growth of 5.6% YoY and stable against last quarter;
- ✚ **Adjusted EBITDA:** reached BRL 120 million in 2Q24 (-14% QoQ), with an **adjusted EBITDA margin** of 20.6%;
- ✚ **Net Debt:** of BRL 1,108 million, with a debt cost below CDI and **leverage index** of 2.2x (financial net debt /EBITDA LTM).

BRL Million (except when indicated)	2Q24	2Q23	Δ 2Q24	1Q24	Δ 2Q24	6M24	6M23	Δ 6M24
<b>Operational Indicator</b>								
Operational Beds (average of the period)	1,602	1,572	1.9%	1,534	4.4%	1,568	1,553	1.0%
Patients-day (total of the period)	110,242	104,206	5.8%	110,479	(0.2%)	220,721	201,728	9.4%
Occupancy rate (average of the period)	75.6%	72.8%	2.8pp	79.1%	(3.5pp)	77.3%	71.8%	5.5pp
<b>Financial Indicator</b>								
Average Ticket (BRL mm / bed)	2.20	2.17	1.5%	2.19	0.6%	2.20	2.18	0.7%
Net Revenue	585.3	554.2	5.6%	582.8	0.4%	1,168.1	1,078.2	8.3%
Gross Profit	174.9	184.5	(5.2%)	193.1	(9.4%)	368.0	363.6	1.2%
<i>Gross Margin</i>	<i>29.9%</i>	<i>33.3%</i>	<i>(3.4pp)</i>	<i>33.1%</i>	<i>(3.2pp)</i>	<i>31.5%</i>	<i>33.7%</i>	<i>(2.2pp)</i>
Adjusted EBITDA	120.3	147.0	(18.1%)	139.5	(13.8%)	259.9	278.9	(6.8%)
<i>Adjusted EBITDA Margin</i>	<i>20.6%</i>	<i>26.5%</i>	<i>(5.9pp)</i>	<i>23.9%</i>	<i>(3.3pp)</i>	<i>22.2%</i>	<i>25.9%</i>	<i>(3.7pp)</i>

## Highlights

### Salvador 2 years anniversary



In May 2024, Mater Dei Salvador hospital completed 2 years of operation, reinforcing its position as a healthcare reference in the region with more than 200,000 consultations and more than 10,000 surgeries. For the surgeries, there was a growth of more than 40% comparing year over year. Since the beginning of its opening, the Hospital has been highlighted by its coverage in more than 40 medical specialties and received, in December 2023, JCI certification (*Joint Commission International*), one of the most important international recognitions that certify the comply of all the patient's safety protocols in healthcare facilities. Regarding medical assistance, over this 2 years, Mater Dei offered and continues to offer a broad services variety aiming all the stages of life.

In addition of being recognized by its excellence in medical care services, Hospital Mater Dei Salvador is also highlighted by its rewarded physical structure, a collaboration between several professionals that worked towards sustainability that the project require.

### New executive board

On July 14, Dra. Lara Salvador Geo was elected by the board of directors to lead the Innovation and Patient Experience areas. Dra. Lara is a doctor, graduated in PUC Minas, with a MBA in strategy, change management and healthcare, and fellow in leadership, by New York University Stern School of Business. She was assistant of the technical director and clinical manager in Rede Mater Dei de Saúde and worked between 2020 and 2022 at Eretz.bio - Hospital Albert Einstein as process specialist and innovation consulting. These movement is part of the succession process that began in November last year. Therefore, Lara is the last member of the third generation in the Company's executive board.

## UTI Top Performer

In the quarter our units were recognized with the awards Efficient ICU (General ICU Hospital Mater Dei Betim-Contagem and Hospital Mater Dei Porto Dias), ICU Top Performer (General ICU Hospital Mater Dei Santo Agostinho, Hospital Mater Dei Santa Genoveva, Hospital Mater Dei Premium and Hospital Mater Dei Santa Clara), and Cardiology Efficient ICU (Coronary Unit Hospital Mater Dei Santo Agostinho), prize-giving by Epimed Solutions, in partnership with the Associação de Medicina Intensiva Brasileira, that recognize the positive clinical results, with efficient allocation of resources of critical patients.



## Acquired units' investments

- ✚ Hospital Premium opened a new emergency room, growing its quality of services and allowing its operational expansion, by a higher admission flow from its new area. In addition, with the implementation of new flows and protocols, we notice a relevant increase in the NPS for the unit.
- ✚ It was finalized the acquisition of strategic lands, next to our EMEC units, in Feira de Santana, aiming to expand this unit that has high occupancy rates. This project is in development phase.
- ✚ It was launched new hospitalization beds in Hospital Santa Genoveva, aiming to modernize this unit and serve the expectations of this promising area that present a strong growth within the national scenario.

## Second debentures issue



On June 5, it was issued the Company's 2<sup>nd</sup> debenture with a value of BRL 200 million, aiming the reinforcement of its cash position, with an interest rate of DI + 0.95% a year, spread lower in 65bps of the 1<sup>st</sup> issue concluded in 2021. The issue got an AA+(bra) rating assigned by Fitch Ratings, with due date for 7 years, half-yearly interest and amortization for the last 2 years. This issue reinforces the resilience of the Company's operating cash flow and its solid fundamentals in the long-term hospital industry.

Earnings release – MATD3

Preparation for Nova Lima opening

The opening of Hospital Mater Dei Nova Lima unit follows the schedule and is planned to be inaugurated on August 23, in advanced stage of being accredited by several healthcare operators. The unit increase in 117 capacity beds Mater Dei's total and represents the expansion of the Company's performance in the metro region of Belo Horizonte.

The new unit was built with concepts of the highest quality standards, offering not only differentiated beds, but also with separated areas for the companion in order to give more privacy to the patient. Within the project it is also available VIP beds with balconies, seeking higher comfort, along the interaction with the external environment. The hospital will have 24 hours emergency room, complete diagnostic medicine service, medical offices, intensive care units and modern surgical center, with more than 40 medical specialties.




# REVENUES

Gross revenue consists mainly of health services, such as admissions, surgeries, oncology, medical appointments, and laboratory tests, among others, either through healthcare operators, self- management and autarchy or out-of-pocket patients.


In the second quarter of 2024, the average number of operational beds reached 1,602, a growth of 30 beds against 2Q23 and 68 beds than 1Q24, with an occupancy rate of 75.6%. The occupancy rate calculation only considers the patients who stay overnight in the hospitals. If Day Patients, those who stay in the hospital for a period of 6 hours or less, were considered, the occupancy rate would increase to 79.2%.

**Quartely evolution of the average operational beds and occupancy rate**




In the second quarter, the volume of patient day hospitalized at Rede Mater Dei increased 5.8% when compared to 2Q23. If it was considered the historical seasonality, it was expected a higher volume of patient day, when compared to 1Q24. However, due to a higher number of dengue fever attendance in the first quarter and a lower occurrence of respiratory illness in the second quarter, this indicator stayed stable.

**% change in number of patients-days vs. 2Q23**



## Earnings release – MATD3

The consolidated average ticket for the second increased 1.5% when compared with 2Q23 and of 0.6% against 1Q24, reaching BRL 2.20 million per used beds. In the year to date the average ticket was BRL 2.20 million per used bed, a growth of 0.7% against the first semester of last year. The composition of the ticket is explained by: (i) hospital mix in the consolidation, (ii) mix of services and procedures; (iii) accreditation portfolio, and (iv) readjustment of the price list with payors. The average ticket variation for the quarter is explained mainly due to the mix of services and procedures.



In 2Q24, the gross revenue reached BRL 663 million, a growth of 7% compared to 2Q23 and stable compared to 1Q24, due to an atypical seasonality, that result in a postponing of some procedures and a lower complex mix than expected. In the six first months of 2024, the gross revenue totaled BRL 1.324 million, an increase of 10% compared to the same period of 2023. The gross revenue is deducted, mainly, by: (i) medical disallowances, (ii) taxes levied on gross revenue (federal contributions and municipal contributions) and (iii) cancellations.

In the second quarter of 2024, net revenue totaled BRL 585 million, a growth of 6% in the annual comparison and stable as of 1Q24. In the semester, net revenue totaled BRL 1,168 million, a growth of 8% against the first semester of 2023. The net revenue increase in the annual comparison do not follow the gross revenue increase, because there was a revision in the provision of medical disallowances in the last quarter of 2023, and in the first semester of 2023 this accounting presented a lower percentage than the first six months of 2024.

BRL Million	2Q24	2Q23	Δ 2Q24	1Q24	Δ 2Q24	6M24	6M23	Δ 6M24
Healthcare operators	612.1	578.6	5.8%	613.5	(0.2%)	1,225.6	1,123.4	9.1%
Out-of-pocket patients	42.3	33.7	25.5%	39.1	8.0%	81.4	66.5	22.5%
Other revenues	8.8	7.2	23.8%	8.3	6.6%	17.2	14.8	16.0%
<b>Gross Revenue</b>	<b>663.2</b>	<b>619.5</b>	<b>7.1%</b>	<b>660.9</b>	<b>0.3%</b>	<b>1,324.1</b>	<b>1,204.6</b>	<b>9.9%</b>
Medical Disallowances	(34.7)	(26.0)	33.5%	(35.1)	(1.1%)	(69.7)	(50.4)	38.5%
Tax and deductions	(43.2)	(39.3)	9.9%	(43.1)	0.3%	(86.3)	(76.0)	13.4%
<b>Net Revenue</b>	<b>585.3</b>	<b>554.2</b>	<b>5.6%</b>	<b>582.8</b>	<b>0.4%</b>	<b>1,168.1</b>	<b>1,078.2</b>	<b>8.3%</b>



## COSTS AND EXPENSES

### Cost of services provided

The costs of services provided mainly include medical supplies and drugs, personnel, physicians, depreciation and amortization, and maintenance and conservation.

In 2Q24, the costs of services provided totaled BRL 411 million, representing 70.1% of net revenues, an increase of 3.4pp in the annual comparison, partially explained by the increase of medical disallowances over gross revenue of healthcare operator, and of 3.2pp against 1Q24.

For the period of 6M24, the cost represented 68.5% of the net revenue, a growth of 2.2pp comparing to the same period of last year. In the annual comparison, both in quarterly and half-year approach, the personnel was the highest line, explained by the collective raises implemented by the Company over the year, including, mainly, the nurses minimum wage.

<i>BRL Million</i>	2Q24	2Q23	Δ 2Q24	1Q24	Δ 2Q24	6M24	6M23	Δ 6M24
Medical Supplies and Drug	(148.2)	(134.9)	9.8%	(133.6)	11.0%	(281.7)	(260.4)	8.2%
<i>% of net revenue</i>	25.3%	24.3%	1.0pp	22.9%	2.4pp	24.1%	24.2%	(0.1pp)
Personnel	(116.4)	(104.5)	11.4%	(112.4)	3.6%	(228.8)	(197.3)	15.9%
<i>% of net revenue</i>	19.9%	18.9%	1.0pp	19.3%	0.6pp	19.6%	18.3%	1.3pp
Medical services	(67.1)	(60.8)	10.4%	(67.6)	(0.8%)	(134.7)	(118.1)	14.1%
<i>% of net revenue</i>	11.5%	11.0%	0.5pp	11.6%	(0.1pp)	11.5%	10.9%	0.6pp
Maintenance and conservation	(27.0)	(22.2)	21.5%	(25.5)	5.9%	(52.5)	(41.8)	25.6%
<i>% of net revenue</i>	4.6%	4.0%	0.6pp	4.4%	0.2pp	4.5%	3.9%	0.6pp
Depreciation and amortization	(21.8)	(20.2)	8.2%	(21.9)	(0.2%)	(43.7)	(41.1)	6.4%
<i>% of net revenue</i>	3.7%	3.6%	0.1pp	3.8%	(0.1pp)	3.7%	3.8%	(0.1pp)
Other costs	(29.9)	(27.1)	10.7%	(28.8)	4.1%	(58.7)	(55.9)	5.0%
<i>% of net revenue</i>	5.1%	4.9%	0.2pp	4.9%	0.2pp	5.0%	5.2%	(0.2pp)
<b>Costs of services provided</b>	<b>(410.5)</b>	<b>(369.7)</b>	<b>11.0%</b>	<b>(389.7)</b>	<b>5.3%</b>	<b>(800.1)</b>	<b>(714.6)</b>	<b>12.0%</b>
<i>% of net revenue</i>	70.1%	66.7%	3.4pp	66.9%	3.2pp	68.5%	66.3%	2.2pp
<b>Gross Margin</b>	<b>174.9</b>	<b>184.5</b>	<b>(5.2%)</b>	<b>193.1</b>	<b>(9.4%)</b>	<b>368.0</b>	<b>363.6</b>	<b>1.2%</b>
<i>% of net revenue</i>	29.9%	33.3%	(3.4pp)	33.1%	(3.2pp)	31.5%	33.7%	(2.2pp)

In these terms, the gross margin totaled 29.9%, with a gross profit of BRL 175 million on 2Q24, representing a decrease of 3.2pp against 1Q24.

## General expenses, administrative and others

General and administrative expenses consist mainly of personnel, depreciation and amortization, and other expenses related to back-office and integration activities.

In 2Q24, the relevance of general and administrative expenses over net revenue reached 13.2%, stable comparing with the same period of last year and a growth of 0.7pp over 1Q24. The quarterly growth is explained, mainly, by the provision of profit shares and annual collective raises. In relation to adjusted net operating expenses, that includes mainly provisions/reversals for legal demands, provisions for doubtful debts and equity pickup, there was an increase of 3.0pp, over net revenue, against 2Q23, partially explained by a reversal in judicial demands of BRL 8,7 million in 2Q23 and higher provision for doubtful debts (revenue cycle) and an increase of 0.3pp when compared to 1Q24.

For the period of the first six months of 2024, the expenses represented 14.0% of net revenue, a growth of 1.5pp in the comparison with the same period last year, due to the same reasons as the annual comparison explained above.

BRL Million	2Q24	2Q23	Δ 2Q24	1Q24	Δ 2Q24	6M24	6M23	Δ 6M24
Personnel	(50.5)	(46.7)	8.1%	(46.3)	9.0%	(96.8)	(91.2)	6.1%
<i>% of net revenue</i>	8.6%	8.4%	0.2pp	8.0%	0.6pp	8.3%	8.5%	(0.2pp)
Depreciation and amortization	(5.7)	(4.7)	21.7%	(5.5)	2.9%	(11.2)	(9.4)	18.9%
<i>% of net revenue</i>	1.0%	0.8%	0.2pp	0.9%	0.1pp	1.0%	0.9%	0.1pp
Third-party services	(14.6)	(14.9)	(2.0%)	(14.5)	0.4%	(29.1)	(29.7)	(1.9%)
<i>% of net revenue</i>	2.5%	2.7%	(0.2pp)	2.5%	-	2.5%	2.8%	(0.3pp)
Other expenses	(6.3)	(6.4)	(1.5%)	(6.2)	1.6%	(12.5)	(13.7)	(8.9%)
<i>% of net revenue</i>	1.1%	1.2%	(0.1pp)	1.1%	-	1.1%	1.3%	(0.2pp)
<b>General and Adm. Expenses</b>	<b>(77.0)</b>	<b>(72.6)</b>	<b>6.1%</b>	<b>(72.6)</b>	<b>6.2%</b>	<b>(149.6)</b>	<b>(144.1)</b>	<b>3.9%</b>
<i>% of net revenues</i>	13.2%	13.1%	0.1pp	12.5%	0.7pp	12.8%	13.4%	(0.6pp)
Other Operational Rev. and Exp.	(6.0)	10.3	(158.5%)	(8.4)	(28.2%)	(14.4)	8.8	(264.2%)
<i>% of net revenue</i>	1.0%	-1.9%	2.9pp	1.4%	(0.4pp)	1.2%	-0.8%	2.0pp
<b>Net operating expenses</b>	<b>(83.1)</b>	<b>(62.3)</b>	<b>33.2%</b>	<b>(81.0)</b>	<b>2.6%</b>	<b>(164.0)</b>	<b>(135.3)</b>	<b>21.3%</b>
<i>% of net revenue</i>	14.2%	11.2%	3.0pp	13.9%	0.3pp	14.0%	12.5%	1.5pp

## EBIT and EBITDA

The disinvestment, announced in May, of Centro Saúde Norte was written off the Company's result, even though the operation was not closed in the quarter (CPC 31), due to the necessity of placing it as an asset available to sale. For that matter, it was recognized a negative value of BRL 744 million in the second quarter, demonstrated in the chart below. To help with the comparisons, for being a non-recurring effect and that not affect cash, we present the EBITDA adjusted of these effects. It was also adjusted preoperational values that refers to Nova Lima, unit that has the opening expected for August 23, 2024, and already have people training in the local.

Adjusted EBITDA in the quarter reached BRL 120 million, lower 18% against 2Q23 and 14% compared to 1Q24. The adjusted EBITDA margin reached 20.6%, this result represents a decrease of 6.0pp compared to 2Q23 and of 3.4pp versus 1Q24. This drop was explained in the cost and expenses, which the highest annual gap comes from a non-recurring effect due to a reversion of an occupation provision held in 2Q23.

In the period of 6M24, adjusted EBITDA reached BRL 260 million with a margin of 22.2%, of which Porto Dias (CSN) represented half of the reduction of BRL 19 million.

BRL Million	2Q24	2Q23	Δ 2Q24	1Q24	Δ 2Q24	6M24	6M23	Δ 6M24
<b>Gross Revenue</b>	<b>663.2</b>	<b>619.5</b>	<b>7.1%</b>	<b>660.9</b>	<b>0.3%</b>	<b>1,324.1</b>	<b>1,204.6</b>	<b>9.9%</b>
Tax, deductions and disallowances	(77.9)	(65.3)	19.3%	(78.1)	(0.4%)	(156.0)	(126.4)	23.4%
<b>Net Revenue</b>	<b>585.3</b>	<b>554.2</b>	<b>5.6%</b>	<b>582.8</b>	<b>0.4%</b>	<b>1,168.1</b>	<b>1,078.2</b>	<b>8.3%</b>
Costs of services provided	(410.5)	(369.7)	11.0%	(389.7)	5.3%	(800.1)	(714.6)	12.0%
Net operating expenses	(83.1)	(62.3)	33.2%	(81.0)	2.6%	(164.0)	(135.3)	21.3%
Impaired asset	(744.1)	-	-	-	-	(744.1)	-	-
<b>EBIT</b>	<b>(652.3)</b>	<b>122.1</b>	<b>(634.1%)</b>	<b>112.1</b>	<b>(681.7%)</b>	<b>(540.2)</b>	<b>228.3</b>	<b>(336.6%)</b>
<i>% of net revenue</i>	<i>-111.4%</i>	<i>22.0%</i>	<i>(133.4pp)</i>	<i>19.2%</i>	<i>(130.6pp)</i>	<i>-46.2%</i>	<i>21.2%</i>	<i>(67.4pp)</i>
Depreciation and amortization	27.5	24.9	10.7%	27.4	0.4%	54.9	50.5	8.7%
<b>EBITDA</b>	<b>(624.8)</b>	<b>147.0</b>	<b>(525.1%)</b>	<b>139.5</b>	<b>(547.8%)</b>	<b>(485.3)</b>	<b>278.9</b>	<b>(274.0%)</b>
<i>% of net revenue</i>	<i>-106.7%</i>	<i>26.5%</i>	<i>(133.2pp)</i>	<i>23.9%</i>	<i>(130.6pp)</i>	<i>-41.5%</i>	<i>25.9%</i>	<i>(67.4pp)</i>
Impairment of assets	744.1	-	-	-	0.0%	744.1	-	-
Nova Lima preoperational	1.0	-	-	-	0.0%	1.0	-	-
<b>Adjusted EBITDA</b>	<b>120.3</b>	<b>147.0</b>	<b>(18.1%)</b>	<b>139.5</b>	<b>(13.8%)</b>	<b>259.9</b>	<b>278.9</b>	<b>(6.8%)</b>
<i>% of net revenue</i>	<i>20.6%</i>	<i>26.5%</i>	<i>(5.9pp)</i>	<i>23.9%</i>	<i>(3.3pp)</i>	<i>22.2%</i>	<i>25.9%</i>	<i>(3.7pp)</i>

## NET FINANCIAL RESULT

In the quarter, net financial result reached negative BRL 47 million, against negative BRL 57 million in 2Q23, this improvement is mostly in the line of interest on loans, financing, installment and acquisitions, with a lower interest rate in the period and negative BRL 49 million in 1Q24.

In the year to date, net financial result was negative BRL 96 million, a drop of 16% against 6M23. This improvement is also related to the line of interest on loans, financing, installment and acquisitions, with a lower interest rate.

<i>BRL Millioimpaired n</i>	2Q24	2Q23	Δ 2Q24	1Q24	Δ 2Q24	6M24	6M23	Δ 6M24
<b>Financial Revenue</b>	<b>14.0</b>	<b>13.8</b>	<b>1.3%</b>	<b>13.8</b>	<b>1.4%</b>	<b>27.8</b>	<b>26.4</b>	<b>5.6%</b>
<b>Financial Expense</b>	<b>(60.6)</b>	<b>(70.5)</b>	<b>(14.0%)</b>	<b>(63.1)</b>	<b>(3.9%)</b>	<b>(123.8)</b>	<b>(140.4)</b>	<b>(11.9%)</b>
<i>Interest on loans, financing, installment and acquisitions</i>	(34.3)	(42.0)	(18.4%)	(36.9)	(7.1%)	(71.2)	(85.8)	(17.1%)
<i>Lease interest</i>	(21.9)	(20.8)	5.4%	(21.6)	1.5%	(43.5)	(41.4)	5.1%
<i>Others</i>	(4.5)	(7.7)	(42.4%)	(4.6)	(3.1%)	(9.1)	(13.2)	(30.9%)
<b>Net Financial Result</b>	<b>(46.6)</b>	<b>(56.7)</b>	<b>(17.8%)</b>	<b>(49.3)</b>	<b>(5.4%)</b>	<b>(95.9)</b>	<b>(114.0)</b>	<b>(15.9%)</b>

## NET INCOME/(LOSS)

In this quarter, adjusted net income totaled BRL 51 million, a drop of 18% compared to the same period last year and of 20% compared to 1Q24. The adjusted net margin hit 8.8% this quarter, representing a decrease of 2.5pp in the annual comparison and of 2.2pp in the quarterly comparison.

As the Centro Saúde Norte disinvestment operation was not finalized on June 30, 2024, there was in the quarter, as well as in the previous ones, an adjustment in net income / (loss) of about BRL 18 million, referring to the provision for deferred income tax liabilities on amortization of goodwill in the Parent Company. After the closing of the operation, this benefit white off. For the quarter, it was used the same adjustments of EBITDA discounted the Income Tax and Social Contribution rate.

For the year to date, adjusted net income reached BRL 115 million, stable in the annual comparison, with an adjusted net income of 9.9%.

<i>BRL Million</i>	2Q24	2Q23	Δ 2Q24	1Q24	Δ 2Q24	6M24	6M23	Δ 6M24
EBIT	(652.3)	122.1	(634.1%)	112.1	(681.7%)	(540.2)	228.3	(336.6%)
Net financial result	(46.6)	(56.7)	(17.8%)	(49.3)	(5.4%)	(95.9)	(114.0)	(15.9%)
<b>EBT</b>	<b>(698.9)</b>	<b>65.4</b>	<b>(1,168.2%)</b>	<b>62.9</b>	<b>(1,211.8%)</b>	<b>(636.1)</b>	<b>114.3</b>	<b>(656.5%)</b>
Income tax and Social Contribution	240.4	(20.5)	(1,273.5%)	(16.9)	(1,522.4%)	223.5	(36.8)	(707.7%)
<b>Net Income</b>	<b>(458.5)</b>	<b>44.9</b>	<b>(1,120.2%)</b>	<b>46.0</b>	<b>(1,097.6%)</b>	<b>(412.6)</b>	<b>77.5</b>	<b>(632.2%)</b>
<i>% of net revenue</i>	<i>-78.3%</i>	<i>8.1%</i>	<i>(86.4pp)</i>	<i>7.9%</i>	<i>(86.2pp)</i>	<i>-35.3%</i>	<i>7.2%</i>	<i>(42.5pp)</i>
Deferred Income tax (goodwill)	18.2	17.9	1.3%	18.0	1.2%	36.1	35.9	0.7%
Impairment of assets	491.1	-	-	-	-	491.1	-	-
Nova Lima preoperational	0.7	-	-	-	-	0.7	-	-
<b>Adjusted Net Income</b>	<b>51.4</b>	<b>62.9</b>	<b>(18.2%)</b>	<b>63.9</b>	<b>(19.6%)</b>	<b>115.3</b>	<b>113.4</b>	<b>1.7%</b>
<i>% of net revenue</i>	<i>8.8%</i>	<i>11.3%</i>	<i>(2.5pp)</i>	<i>11.0%</i>	<i>(2.2pp)</i>	<i>9.9%</i>	<i>10.5%</i>	<i>(0.6pp)</i>

## DEBT AND LEVERAGE

In the second quarter of 2024, the total debt was of BRL 1,449 million, higher 15% than the final amount of last quarter, explained by the 2<sup>nd</sup> debentures issue of BRL 200 million.

The leverage index (financial net debt / EBITDA LTM) reached 2.2x in 2Q24.

BRL Million	2Q24	2Q23	Δ 2Q24	1Q24	Δ 2Q24
Short-term debt	75.8	56.8	33.5%	97.9	(22.6%)
Long-term debt	1,364.8	1,213.2	12.5%	1,170.4	16.6%
Derivative financial instruments (+/-) <sup>1</sup>	8.1	(13.6)	(159.9%)	(5.4)	(250.4%)
<b>Total debt<sup>2</sup></b>	<b>1,448.8</b>	<b>1,256.5</b>	<b>15.3%</b>	<b>1,262.9</b>	<b>14.7%</b>
Cash and equivalents and financial investments	324.6	316.9	2.4%	241.6	34.4%
Cash and equivalents and financial investments of asset available to sell	16.4	-	-	-	-
<b>Net Debt</b>	<b>1,107.8</b>	<b>939.6</b>	<b>17.9%</b>	<b>1,021.3</b>	<b>8.5%</b>
EBITDA LTM <sup>3</sup>	505.5	518.5	(2.5%)	533.3	(5.2%)
<b>Net debt/EBITDA (LTM)</b>	<b>2.2x</b>	<b>1.8x</b>	<b>0.4</b>	<b>1.9x</b>	<b>0.3</b>


1. Derivative instrument (swap) related to the exchange of an IPCA rate to a CDI rate in the Banco do Nordeste (BNB) debt.

2. According to the covenant of the debentures issue of the Company, consider the sum of the balances of loans, financing and debentures net of all derivative financial instruments (current and non-current). It does not consider liabilities for lease and acquisition of companies payable.


3. According to the covenant of the debentures issue of the Company, EBITDA is the earnings before interest, taxes, depreciation and amortization, impaired asset and equity pickup.

Mater Dei's weighted average amortization term is 4.7 years. The cost of debt for 2Q24 was of CDI – 0.5% a year.

Debt payment schedule<sup>4</sup> (BRL Mm)



Average Cost of debt and Indexation




4. Does not consider transaction cost.

## CASH FLOW

Considering the position of cash, cash equivalents and financial investments, the company ended 2Q24 with BRL 325 million, a growth of 2% compared to the cash at the end of the previous year.

In the semester quarter of 2024, cash generated by operations before working capital amounted BRL 296 million with BRL 160 million being consumed by changes in assets and liabilities (accounts payable, suppliers, inventories, among others). To complete the net cash flow generated by operating activities, we had BRL 80 million paid in interest and income tax and social contribution.

Investment activities consumed BRL 168 million, of which BRL 138 million was for the payment of expansion and maintenance Capex and intangible assets, mainly related to Nova Lima’s unit construction. In this same investment account, we have the payment of acquisitions in the amount of BRL 29 million, relating mainly to the payment of the third installment of the purchase of Mater Dei Premium in the first quarter. In addition, there was an inflow of BRL 125 million in financing activities, with BRL 200 million from the 2<sup>nd</sup> debentures issue in July, offset by dividends payment of BRL 28 million and payment of loans and leasing and the generation of BRL 2 million in investment income, net of redemptions.



## APPENDIX

## P&amp;L

<i>Consolidated (BRL thousand)</i>	2Q24	2Q23	1Q24	6M24	6M23
<b>Gross Revenue</b>	<b>663,209</b>	<b>619,451</b>	<b>660,939</b>	<b>1,324,148</b>	<b>1,204,625</b>
Healthcare Operator	612,081	578,623	613,499	1,225,580	1,123,390
Out-of-pocket patients	42,279	33,680	39,139	81,418	66,451
Other revenue	8,849	7,148	8,301	17,150	14,784
<b>Taxes, Deductions and Disallowance</b>	<b>(77,866)</b>	<b>(65,296)</b>	<b>(78,140)</b>	<b>(156,006)</b>	<b>(126,411)</b>
<b>Net Revenue</b>	<b>585,343</b>	<b>554,155</b>	<b>582,799</b>	<b>1,168,142</b>	<b>1,078,214</b>
<b>Costs of services provided</b>	<b>(410,455)</b>	<b>(369,680)</b>	<b>(389,691)</b>	<b>(800,146)</b>	<b>(714,592)</b>
Medical Supplies and drugs	(148,187)	(134,909)	(133,559)	(281,746)	(260,435)
Personnel	(116,418)	(104,545)	(112,403)	(228,821)	(197,361)
Medical services	(67,091)	(60,792)	(67,613)	(134,704)	(118,061)
Maintenance and conservation	(26,990)	(22,216)	(25,478)	(52,468)	(41,763)
Depreciation and amortization	(21,841)	(20,193)	(21,880)	(43,721)	(41,095)
Other costs	(29,928)	(27,025)	(28,758)	(58,686)	(55,877)
<b>Gross profit</b>	<b>174,888</b>	<b>184,475</b>	<b>193,108</b>	<b>367,996</b>	<b>363,622</b>
<b>General and administrative expenses</b>	<b>(77,037)</b>	<b>(72,642)</b>	<b>(72,569)</b>	<b>(149,606)</b>	<b>(144,057)</b>
Personnel	(50,488)	(46,709)	(46,336)	(96,824)	(91,252)
Depreciation and amortization	(5,674)	(4,661)	(5,514)	(11,188)	(9,410)
Third-party services	(14,576)	(14,875)	(14,517)	(29,092)	(29,668)
Other expenses	(6,299)	(6,397)	(6,202)	(12,502)	(13,727)
<b>Equity pickup</b>	<b>(225)</b>	<b>2,281</b>	<b>616</b>	<b>(457)</b>	<b>2,022</b>
<b>Other operating income (expenses)</b>	<b>(5,803)</b>	<b>8,019</b>	<b>(9,008)</b>	<b>(13,964)</b>	<b>6,764</b>
<b>Impairment of assets- CPC 31</b>	<b>(744,142)</b>	<b>-</b>	<b>-</b>	<b>(744,142)</b>	<b>-</b>
<b>Earnings before financial income and expenses</b>	<b>(652,319)</b>	<b>122,133</b>	<b>112,147</b>	<b>(540,173)</b>	<b>228,351</b>
Financial revenue	14,019	13,843	13,827	27,846	26,357
Financial expenses	(60,646)	(70,545)	(63,114)	(123,760)	(140,400)
<b>Net financial result</b>	<b>(46,627)</b>	<b>(56,702)</b>	<b>(49,287)</b>	<b>(95,914)</b>	<b>(114,043)</b>
<b>Earnings before income tax and social contribution</b>	<b>(698,946)</b>	<b>65,431</b>	<b>62,860</b>	<b>(636,087)</b>	<b>114,308</b>
<b>Income Tax and Social Contribution</b>	<b>240,407</b>	<b>(20,487)</b>	<b>(16,901)</b>	<b>223,506</b>	<b>(36,782)</b>
<b>Net Income / (Loss)</b>	<b>(458,539)</b>	<b>44,944</b>	<b>45,959</b>	<b>(412,581)</b>	<b>77,526</b>
<i>Deferred Income tax (goodwill)</i>	18,162	17,931	17,954	36,116	35,862
<i>Nova Lima preoperational</i>	651	-	-	651	-
<i>Impairment of assets</i>	491,134	-	-	491,134	-
<b>Adjusted net income</b>	<b>51,408</b>	<b>62,875</b>	<b>63,913</b>	<b>115,320</b>	<b>113,388</b>
Net income attributed to controlling partners	(464,267)	38,092	42,183	(422,084)	65,305
Net income attributed to noncontrolling partners	5,728	6,852	3,776	9,505	12,221

<i>(BRL thousand)</i>	2Q24	2Q23	1Q24	6M24	6M23
<b>EBIT</b>	<b>(652,319)</b>	<b>122,133</b>	<b>112,147</b>	<b>(540,173)</b>	<b>228,350</b>
Depreciation and amortization	27,515	24,854	27,394	54,909	50,505
<b>EBITDA</b>	<b>(624,804)</b>	<b>146,987</b>	<b>139,541</b>	<b>(485,264)</b>	<b>278,855</b>
<i>Nova Lima preoperational</i>	986	-	-	986	-
<i>Impairment of assets</i>	744,142	-	-	744,142	-
<b>Adjusted EBITDA</b>	<b>120,324</b>	<b>146,987</b>	<b>139,541</b>	<b>259,864</b>	<b>278,855</b>



## Balance Sheet

<i>Consolidated (BRL thousand)</i>	<b>06/30/2024</b>	<b>06/30/2023</b>	<b>12/31/2023</b>
<b>Asset</b>			
<b>Current</b>			
Cash and Cash Equivalents	269,395	223,953	227,302
Financial Investments	55,186	92,911	91,831
Accounts receivable	645,825	735,657	798,581
Inventories	52,801	65,156	63,165
Derivatives	-	13,557	1,054
Construction Reimbursement	40,125	39,598	38,143
Construction assets to be deployed	-	5,610	-
Other current assets	61,670	53,799	38,097
	<b>1,125,002</b>	<b>1,230,241</b>	<b>1,258,173</b>
Asset available to sale	988,894	-	-
<b>Total current assets</b>	<b>2,113,896</b>	<b>1,230,241</b>	<b>1,258,173</b>
<b>Non-current</b>			
Construction Reimbursement	297,776	301,622	305,142
Judicial deposits	47,292	64,704	48,138
Deferred taxes	263,872	47,625	58,127
Derivatives	-	-	9,800
Investments	16,820	18,757	18,812
Right of use	595,457	767,511	753,232
Fixed Assets	814,346	708,395	764,594
Intangible assets	728,259	1,847,933	1,853,209
Other non-current assets	51,160	96,314	102,224
<b>Total non-current assets</b>	<b>2,814,982</b>	<b>3,852,861</b>	<b>3,913,278</b>
<b>Total Assets</b>	<b>4,928,878</b>	<b>5,083,102</b>	<b>5,171,451</b>
<b>Liabilities</b>			
<b>Current</b>			
Suppliers	127,543	122,696	148,701
Loans and financing	75,837	56,810	52,205
Derivatives	786	-	-
Leasing	63,526	81,759	81,228
Salaries & social security contribution	78,274	92,326	74,904
Taxes and contributions payable	16,865	28,321	37,288
Installment payment of taxes	7,643	4,562	6,644
Accounts payable of company acquisition	34,106	35,624	36,931
Dividends payable	-	3,108	36,221
Other current liabilities	9,257	12,622	11,453
	<b>413,837</b>	<b>437,828</b>	<b>485,575</b>
Liabilities available to sale	435,349	-	-
<b>Total current liabilities</b>	<b>849,186</b>	<b>437,828</b>	<b>485,575</b>
<b>Non-current</b>			
Loans and financing	1,364,845	1,213,206	1,202,660
Derivatives	7,336	-	-
Leasing	605,525	761,995	762,274
Redemption liability	78,548	399,784	422,171
Installment payment of taxes	78,411	9,088	4,695
Deferred taxes liabilities	1,798	82,539	99,715
Accounts payable of company acquisition	155,431	166,238	174,778
Provision for contingencies	195,584	262,287	255,417
Other non-current liabilities	11,807	8,775	9,942
<b>Total non-current liabilities</b>	<b>2,499,285</b>	<b>2,903,912</b>	<b>2,931,652</b>
<b>Equity Capital</b>			
Capital	1,301,019	1,301,019	1,301,019
Capital reserves	380,925	370,242	376,142
Income reserves	(25,594)	371,425	397,054
(-) Treasury stocks	(15,801)	(1,962)	(1,962)
Equity valuation adjustment	(88,572)	(393,373)	(417,112)
<b>Total equity attributable to the Company's shareholder</b>	<b>1,551,977</b>	<b>1,647,351</b>	<b>1,655,141</b>
Share of noncontrolling shareholders	28,430	94,011	99,083
<b>Total Shareholders' equity</b>	<b>1,580,407</b>	<b>1,741,362</b>	<b>1,754,224</b>
<b>Total Liabilities</b>	<b>4,928,878</b>	<b>5,083,102</b>	<b>5,171,451</b>

## Cash Flow

<i>Consolidated (BRL thousand)</i>	<b>6M24</b>	<b>6M23</b>
<b><u>Cash flow from operating activities</u></b>		
Net profit for the period	(412.581)	77.526
<b>Adjustments to reconcile net income to cash from operations</b>		
Depreciation and amortization	54.909	50.578
Write-off of fixed and intangible assets	1.829	3.416
Establishment (reversal) of allowance for doubtful accounts	14.482	4.467
Establishment (reversal) of provision for disallowances	36.104	17.248
Establishment (reversal) of provision and restatement for contingencies	5.360	3.231
Share-Based Payment provision	4.783	5.804
Equity pickup gains	457	(2.022)
Derivative gains	(1.491)	(937)
Income from financial investments	(12.402)	(13.949)
Net financial expenses	104.867	121.427
Establishment of Installment payment of taxes	938	-
Loss of impairment of assets	744.142	-
Provision for income tax and social contribution - current & deferred	(244.933)	15.271
	<b>296.464</b>	<b>282.060</b>
<b>Variations in Operating Assets and Liabilities</b>		
Accounts Receivable	(120.835)	(148.025)
Inventories	(5.123)	(870)
Other assets	(11.898)	(5.856)
Judicial deposits	(2.382)	(7.028)
Suppliers	4.025	(16.482)
Salaries and social security contributions	18.660	21.822
Taxes and contributions payable	7.883	19.298
Tax installments	(3.398)	(2.916)
Variations in Operating Assets from assets available to sale	(46,458)	-
Other liabilities	(737)	(2.194)
	<b>(160,263)</b>	<b>(142.251)</b>
Income tax and social contributions paid	(17,430)	(18.293)
Interest paid	(73,115)	(78.888)
<b>Net cash generated by operating activities</b>	<b>45,656</b>	<b>42.628</b>
<b><u>Cash Flow of Investment activities</u></b>		
Acquisition of fixed assets	(126.007)	(76.798)
Acquisition of intangible assets	(5.057)	(7.607)
Developments with construction to be deployed	(7.395)	(19.786)
Investment acquisition	(95)	-
Controlled consolidation of initial cash	(29.160)	(38.083)
Financial investments made, net redemptions	39.003	52.922
<b>Net cash used in investment activities</b>	<b>(128.711)</b>	<b>(89.352)</b>
<b><u>Cash flow from financing activities</u></b>		
Loans and financing	206.893	78.069
Payments of loans and financing	(20.422)	(14.247)
Lease payments	(18.945)	(12.773)
Derivative settlement	(121)	(2.204)
Treasury stocks	(13.839)	-
Dividends paid	(28.418)	(24.582)
<b>Net cash generated (used) in financing activities</b>	<b>125.148</b>	<b>24.263</b>
<b>INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>42.093</b>	<b>(22.461)</b>
Cash and cash equivalents at the beginning of the period	227.302	246.414
Cash and cash equivalents at the end of the period	269.395	223.953
<b>INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>42.093</b>	<b>(22.461)</b>

## GLOSSARY AND OTHER INFORMATION

### Glossary

- **AoP:** Average of period
- **LTM:** Last Twelve Months
- **Net Debt:** Short-term and long-term debt, net of cash, cash equivalents and short-term investments. The term "net debt" is a measure of the Company and may not be comparable with similar terms adopted by other companies.
- **IFRS 16:** As of January 1<sup>st</sup>, 2019, all companies had to adapt to the new rules of IFRS 16. With this new standard, lessees now have to recognize the asset of rights over leased assets and the liability of future payments for medium or long-term leases, including operating leases. The biggest impact we had was on the real estate lease contracts of our operational and administrative units.
- **EBITDA:** Earnings before Interest, Taxes, Depreciation and Amortization
- **EBITDA Margin:** EBITDA divided by net revenue
- **EBIT:** Earnings before Interest and Taxes
- **SELIC:** is the Brazilian economy's basic interest rate
- **CDI:** Interbank Deposit Certificate
- **IPCA:** Extended National Consumer Price Index
- **Occupancy rate:** Number of beds occupied by patients per day added up over a given period, divided by the number of beds that were operational each day added up during the same period

### About Rede Mater Dei de Saúde

Rede Mater Dei de Saúde is an integrated platform that provides hospital and cancer services, being a national reference in health and the largest private hospital network in Minas Gerais. The Company has more than 2,500 beds of capacity in its 9 units located in the metropolitan region of Belo Horizonte ("MRBH"), Salvador, Belém, Uberlândia, Goiânia and Feira de Santana.

Rede Mater Dei has a clinical expertise that is recognized by patients, medical community, healthcare operators, suppliers, and relevant sectors of the Brazilian Society, and focuses on innovation and medical pioneering.

### Relationship with independent auditors

In accordance with CVM Resolution CVM 162/22, we inform that our policy for hiring independent auditors considers the best governance principles, which reserve the auditor's independence, in accordance with internationally accepted criteria.

*For additional Investor Relations information, please access the website: <https://ri.materdei.com.br/en/> or e-mail [ri@materdei.com.br](mailto:ri@materdei.com.br)*

*This material contains summary information, which is not intended to be complete and should not be considered by shareholders or potential investors as an investment recommendation. Information about Mater Dei, its activities, economic and financial situation, and the risks inherent to its activities, as well as its financial statements, can be obtained on the world wide web, on the Mater Dei website (<https://ri.materdei.com.br/en/>)*

# MaterDei

Rede de Saúde

 MaterDei  
Hospital Santo Agostinho

 MaterDei  
Hospital Betim-Contagem

 MaterDei  
Hospital Nova Lima

 MaterDei  
Hospital Contorno

 MaterDei  
Hospital Salvador

 MaterDei  
Rede de Saúde



 MaterDei  
Rede de Saúde



 MaterDei  
Rede de Saúde



 MaterDei  
Rede de Saúde



 MaterDei  
Rede de Saúde



 MaterDei  
Rede de Saúde



TUDO  
PRA  
VOCÊ  
FICAR  
BEM